STOCK TITAN

Summit Therapeutics co-CEO spouse exercises 500K-share option

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Summit Therapeutics Inc. (SMMT) Co-Chief Executive Officer Robert W. Duggan reported that his spouse exercised an option for 500,000 common shares on November 16, 2026, at an exercise price of $1.06 per share. Afterward, the spouse held 531,000 common shares indirectly and 800,000 options. No Rule 10b5-1 plan is reported.

Insider DUGGAN ROBERT W
Role Co-Chief Executive Officer
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F3 500,000 $0.00 $0.00
Exercise Common Stock F1, F2 500,000 $1.06 $530K
Holding Common Stock -- -- --
Holding Common Stock F2 -- -- --
Holding Common Stock F2 -- -- --
Holding Common Stock F2 -- -- --
Holdings After Transaction: Stock Option (right to buy) — 800,000 options (Indirect, By Spouse); Common Stock — 531,000 shares (Indirect, By Spouse); Common Stock — 573,883,879 shares (Direct); Common Stock — 25,824,474 shares (Indirect, By the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee); Common Stock — 76,680 shares (Indirect, Immediate family member of Spouse); Common Stock — 10,199,776 shares (Indirect, By the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee)
Footnotes (3)
  1. F1. On November 16, 2026, the Spouse of Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
  2. F2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
  3. F3. The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Common shares acquired through option exercise 500,000 shares November 16, 2026
Option exercise price $1.06 per share Exercise on November 16, 2026
Indirect common shares held after exercise 531,000 shares Held by the Co-Chief Executive Officer’s spouse after the November 16, 2026 exercise
Options held after exercise 800,000 options Reported after the November 16, 2026 exercise; expiration date June 28, 2032
exercise price financial
"at an exercise price of $1.06 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
performance criteria financial
"subject to certain performance criteria"
service-based vesting requirements financial
"only the service-based vesting requirements to continue to be satisfied"
beneficial ownership regulatory
"disclaims beneficial ownership of these securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did Robert W. Duggan’s spouse acquire in the SMMT option exercise?

The spouse acquired 500,000 Summit Therapeutics common shares by exercising an option on November 16, 2026, at $1.06 per share. The spouse held 531,000 common shares indirectly after the exercise.

What were the vesting terms for the SMMT option?

The option was granted to the Co-Chief Executive Officer’s spouse on June 28, 2022, subject to performance criteria. It vested as to 260,000 shares on August 23, 2024, and 520,000 shares on April 29, 2025; the remaining 520,000 were to vest in three equal annual installments, with the first installment occurring October 13, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DUGGAN ROBERT W

(Last)(First)(Middle)
C/O SUMMIT THERAPEUTICS INC.
601 BRICKELL KEY DRIVE SUITE 1000

(Street)
MIAMI FLORIDA 33131

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Summit Therapeutics Inc. [ SMMT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirectorX10% Owner
XOfficer (give title below)Other (specify below)
Co-Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M(1)500,000A$1.06531,000(2)IBy Spouse
Common Stock573,883,879D
Common Stock25,824,474(2)IBy the Mahkam Zanganeh Revocable Trust, with the Spouse of Reporting Person as Trustee
Common Stock76,680(2)IImmediate family member of Spouse
Common Stock10,199,776(2)IBy the Shaun Zanganeh Irrevocable Trust, with the Spouse of Reporting Person as Trustee
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.0611/16/2026M(1)500,000 (3)06/28/2032Common Stock500,000$0800,000IBy Spouse
Explanation of Responses:
1. On November 16, 2026, the Spouse of Reporting Person exercised an option to purchase 500,000 shares of the Issuer's common stock at an exercise price of $1.06 per share.
2. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
3. The option was granted to the Spouse of Reporting Person on June 28, 2022, subject to certain performance criteria. On August 23, 2024, based on satisfaction of certain performance criteria, the option vested as to 260,000 shares. On April 29, 2025, the option was modified to require only the service-based vesting requirements to continue to be satisfied in order to become fully vested; the option vested as to 520,000 shares on April 29, 2025 and the remaining 520,000 will vest in three equal annual installments, with the first such installment having occurred on October 13, 2025.
Remarks:
/s/ Robert W. Duggan11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading